Moderna, Inc. - Common Stock (MRNA)

What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 finan...

Profitability returned as international partnerships offset a norovirus setback.

Moderna (NASDAQ:MRNA) raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international partnerships supported results. The company reported revenue of $1.3 billion, up 29% from a year ear

Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.

Biotechnology company Moderna (NASDAQ:MRNA) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 29.2% year on year to $1.31 b...

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting earnings this Friday before market hours. Here’s what to expect. Moderna beat analysts’ revenue...

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.

Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.

The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future.

Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma.

Moderna stock has skyrocketed this year.

These biotechs’ valuations are through the roof.

Moderna shares have outperformed tech giants this year.

Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di

The stock fell 17% in one trading session.